Impact of dynamic contrast-enhanced MRI in 1.5 T versus 3 T MRI for clinically significant prostate cancer detection.
暂无分享,去创建一个
P. Albers | D. Blondin | G. Antoch | C. Arsov | L. Schimmöller | T. Ullrich | M. Boschheidgen | F. Ziayee | L. Wilms | M. Vach
[1] P. Albers,et al. MRI grading for the prediction of prostate cancer aggressiveness , 2021, European Radiology.
[2] P. Albers,et al. Comparison and prediction of artefact severity due to total hip replacement in 1.5 T versus 3 T MRI of the prostate. , 2021, European journal of radiology.
[3] K. Iczkowski,et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. , 2021, The American journal of surgical pathology.
[4] T. Benkert,et al. Advanced zoomed diffusion-weighted imaging vs. full-field-of-view diffusion-weighted imaging in prostate cancer detection: a radiomic features study , 2020, European Radiology.
[5] P. Albers,et al. Advanced diffusion weighted imaging of the prostate: Comparison of readout-segmented multi-shot, parallel-transmit and single-shot echo-planar imaging. , 2020, European journal of radiology.
[6] A. Padhani,et al. Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question , 2020, Journal of magnetic resonance imaging : JMRI.
[7] M. Papotti,et al. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI) , 2019, Abdominal Radiology.
[8] L. Holmberg,et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29‐Year Follow‐up , 2018, The New England journal of medicine.
[9] F. Fennessy,et al. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy , 2018, Abdominal Radiology.
[10] S. Byun,et al. Diagnostic performance of diffusion-weighted imaging for prostate cancer: Peripheral zone versus transition zone , 2018, PloS one.
[11] Tao Peng,et al. Diagnostic Performance of Biparametric MRI for Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. , 2018, AJR. American journal of roentgenology.
[12] L. Brunese,et al. Biparametric MRI of the prostate. , 2017, Turkish journal of urology.
[13] P. Choyke,et al. Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. , 2017, Radiology.
[14] Fernando Calamante,et al. Gadolinium deposition in the brain: summary of evidence and recommendations , 2017, The Lancet Neurology.
[15] P. Albers,et al. Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: A prospective comparison study of image quality. , 2017, European journal of radiology.
[16] James S. Babb,et al. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection. , 2017, Radiology.
[17] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[18] N. Lumen,et al. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA. , 2017, Clinical radiology.
[19] Katarzyna J Macura,et al. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. , 2016, European urology.
[20] Baris Turkbey,et al. DCE MRI of prostate cancer , 2016, Abdominal Radiology.
[21] T. Scheenen,et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Management: Current Status and Future Perspectives , 2015, Investigative radiology.
[22] David F Kallmes,et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. , 2015, Radiology.
[23] T. Sone,et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. , 2011, AJR. American journal of roentgenology.
[24] F. Beuvon,et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer , 2011, Prostate Cancer and Prostatic Diseases.